Literature DB >> 25969499

A perianal presentation of myeloid sarcoma.

Navraj S Nagra1, Emilio Lozano2, Elizabeth Soilleux3, Pepe Mullerat2.   

Abstract

Myeloid sarcoma is a rare tumour associated with acute myeloid leucaemia (AML). Infrequently, it can occur in myelodysplastic/myeloproliferative overlap syndrome conditions such as chronic monomyelocytic leucaemia (CMML), where it often heralds the transformation towards an AML. We discuss a rare presentation of myeloid sarcoma in the perianal region of a 51-year-old man, who was seen by various clinicians and treated for haemorrhoids and perianal abscess. There were no gross abnormalities in initial haematological investigations and the patient was systemically well. A histological biopsy demonstrated myeloid sarcoma and bone marrow aspirate, and trephine confirmed CMML transforming to AML. Treatment of myeloid sarcoma is dependent on whether there is associated AML in the bone marrow. Dual chemotherapy with cytarabine and daunorubicin remains the gold standard treatment in these patients. Sending histology samples of atypical lesions when performing incision and drainage procedures is extremely important, as it contributes to early detection of rare and malignant tissue diagnoses. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25969499      PMCID: PMC4434259          DOI: 10.1136/bcr-2015-209832

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

Review 1.  Comparison in treatments of nonleukemic granulocytic sarcoma: report of two cases and a review of 72 cases in the literature.

Authors:  Kunihiko Yamauchi; Masami Yasuda
Journal:  Cancer       Date:  2002-03-15       Impact factor: 6.860

2.  Perianal infections in patients with leukemia: importance of the course of neutrophil count.

Authors:  Y Büyükaşik; O I Ozcebe; N Sayinalp; I C Haznedaroğlu; O O Altundağ; O Ozdemir; S Dündar
Journal:  Dis Colon Rectum       Date:  1998-01       Impact factor: 4.585

Review 3.  Granulocytic sarcoma: a systematic review.

Authors:  Asu Fergun Yilmaz; Guray Saydam; Fahri Sahin; Yusuf Baran
Journal:  Am J Blood Res       Date:  2013-12-18

4.  Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.

Authors:  Anna M Jankowska; Hideki Makishima; Ramon V Tiu; Hadrian Szpurka; Yun Huang; Fabiola Traina; Valeria Visconte; Yuka Sugimoto; Courtney Prince; Christine O'Keefe; Eric D Hsi; Alan List; Mikkael A Sekeres; Anjana Rao; Michael A McDevitt; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

5.  How I treat extramedullary acute myeloid leukemia.

Authors:  Richard L Bakst; Martin S Tallman; Dan Douer; Joachim Yahalom
Journal:  Blood       Date:  2011-07-27       Impact factor: 22.113

6.  Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia.

Authors:  Apostolia-Maria Tsimberidou; Hagop M Kantarjian; Sijin Wen; Michael J Keating; Susan O'Brien; Mark Brandt; Sherry Pierce; Emil J Freireich; L Jeffrey Medeiros; Elihu Estey
Journal:  Cancer       Date:  2008-09-15       Impact factor: 6.860

7.  Granulocytic sarcoma in nonleukemic patients.

Authors:  J M Meis; J J Butler; B M Osborne; J T Manning
Journal:  Cancer       Date:  1986-12-15       Impact factor: 6.860

8.  Granulocytic sarcoma: a clinicopathologic study of 61 biopsied cases.

Authors:  R S Neiman; M Barcos; C Berard; H Bonner; R Mann; R E Rydell; J M Bennett
Journal:  Cancer       Date:  1981-09-15       Impact factor: 6.860

9.  Isolated chloroma: the effect of early antileukemic therapy.

Authors:  K R Imrie; M J Kovacs; D Selby; J Lipton; B J Patterson; D Pantalony; P Poldre; B Y Ngan; A Keating
Journal:  Ann Intern Med       Date:  1995-09-01       Impact factor: 25.391

10.  Chloroma of perianal region masquerading as perianal abscess.

Authors:  Rajeev Sen; Sunita Singh; Mahapatra S Qury; Sanjay Marwah; Garima Aggarwal; Shyam Singla
Journal:  Indian J Dermatol       Date:  2013-01       Impact factor: 1.494

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.